Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase I Trial of a Single Intravitreal Injection of REDD14NP to Patients With CNV Secondary to Wet AMD

Study:

A Phase 1 Open-Label, Dose Escalation Trial of REDD14NP Delivered by a Single Intravitreal Injection to Patients With Choroidal Neovascularization (CNV) Secondary to Exudative Age-Related Macular Degeneration ("Wet AMD")

Rationale:

n/a

Purpose:

This is an open-label, dose escalation study in which patents will receive a single intravitreal injection of REDD14NP. The primary objective of the study is to determine the safety and pharmacokinetics of REDD14NP when administered as a single intravitreal injection.

Study Status: Recruiting

Recruiting:
Lynn Bartko, RN, BSN 216-444-7137 bartkol@ccf.org

Condition Intervention Phase
Age-Related Macular Degeneration (AMD) Drug: REDD14NP Phase 1

Verified by Quark Pharmaceuticals October, 2007

Sponsored by: Quark Pharmaceuticals
Information provided by: Quark Pharmaceuticals
ClinicalTrials.gov identifier: NCT00455481

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study

Cole Eye Institute Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

James M Klancnik, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site